• Je něco špatně v tomto záznamu ?

Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies

M. Fumery, D. Duricova, C. Gower-Rousseau, V. Annese, L. Peyrin-Biroulet, PL. Lakatos,

. 2016 ; 43 (3) : 346-55. [pub] 20151118

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, U.S. Gov't, Non-P.H.S., přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027943
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 18 měsíci
Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem
Wiley Free Content od 1997 do Před 18 měsíci

BACKGROUND: A better knowledge of the natural history of disabling chronic diseases is essential to improve patient management, evaluate the impact of treatment strategies and provide predictors for disabling disease and comprehensive information for patients. AIM: To summarise our current knowledge issued from population-based studies of the natural history of ulcerative colitis (UC) in children. METHODS: We searched MEDLINE (source PubMed) and international conference abstracts, and included all population-based studies that evaluated long-term outcome of paediatric-onset (<17 years at diagnosis) UC. RESULTS: A total of 26 population-based studies were considered in this review from the total of 61 articles or abstracts screened. Most patients presented disease extension and about two-thirds of patients had pancolitis at the end of follow-up. One-half of patients experienced extra-intestinal manifestations and primary sclerosing cholangitis was observed in 5-10% of patients. Overall, patients did not appear to have any significant growth retardation or delayed puberty. About two-thirds of patients required corticosteroid therapy and up to 25% were steroid dependent. An increased use of thiopurines was observed and the most recent data indicate that up to one-half of patients were exposed to thiopurines and 10-30% were exposed to anti-tumour necrosis factor. One-half of patients required hospitalisations and 20% of patients required colectomy after a follow-up of 10 years. CONCLUSIONS: Paediatric-onset UC is characterised by a high rate of disease extension. About 20% of patients had been operated at 10-year follow-up. New population-based studies are needed to evaluate the impact of new treatment strategies comprising immunosuppressants and biologics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027943
003      
CZ-PrNML
005      
20161018094506.0
007      
ta
008      
161005s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/apt.13478 $2 doi
024    7_
$a 10.1111/apt.13478 $2 doi
035    __
$a (PubMed)26582737
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fumery, M $u Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France.
245    10
$a Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies / $c M. Fumery, D. Duricova, C. Gower-Rousseau, V. Annese, L. Peyrin-Biroulet, PL. Lakatos,
520    9_
$a BACKGROUND: A better knowledge of the natural history of disabling chronic diseases is essential to improve patient management, evaluate the impact of treatment strategies and provide predictors for disabling disease and comprehensive information for patients. AIM: To summarise our current knowledge issued from population-based studies of the natural history of ulcerative colitis (UC) in children. METHODS: We searched MEDLINE (source PubMed) and international conference abstracts, and included all population-based studies that evaluated long-term outcome of paediatric-onset (<17 years at diagnosis) UC. RESULTS: A total of 26 population-based studies were considered in this review from the total of 61 articles or abstracts screened. Most patients presented disease extension and about two-thirds of patients had pancolitis at the end of follow-up. One-half of patients experienced extra-intestinal manifestations and primary sclerosing cholangitis was observed in 5-10% of patients. Overall, patients did not appear to have any significant growth retardation or delayed puberty. About two-thirds of patients required corticosteroid therapy and up to 25% were steroid dependent. An increased use of thiopurines was observed and the most recent data indicate that up to one-half of patients were exposed to thiopurines and 10-30% were exposed to anti-tumour necrosis factor. One-half of patients required hospitalisations and 20% of patients required colectomy after a follow-up of 10 years. CONCLUSIONS: Paediatric-onset UC is characterised by a high rate of disease extension. About 20% of patients had been operated at 10-year follow-up. New population-based studies are needed to evaluate the impact of new treatment strategies comprising immunosuppressants and biologics.
650    _2
$a hormony kůry nadledvin $7 D000305
650    _2
$a kolektomie $7 D003082
650    _2
$a ulcerózní kolitida $x epidemiologie $x patofyziologie $x terapie $7 D003093
650    _2
$a management nemoci $7 D019468
650    _2
$a progrese nemoci $7 D018450
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a přehledy $7 D016454
700    1_
$a Duricova, D $u Department of Gastroenterology, Univerzity Karlovy, Prague, Czech Republic. EPICOM, European Crohn & Colitis Organization, Vienna, Austria.
700    1_
$a Gower-Rousseau, C $u EPICOM, European Crohn & Colitis Organization, Vienna, Austria. Public Health, Epidemiology and Economic Health, Epimad Registry, Maison Régionale de la Recherche Clinique, Centre Hospitalier Universitaire Régional, 59037, Lille Cedex, France. Lille Inflammation Research International Center LIRIC - UMR 995 Inserm/Université Lille 2/CHRU de Lille, Equipe IBD and Environmental Factors: Epidemiology and Functional Analyses, Lille University, Lille, France.
700    1_
$a Annese, V $u EPICOM, European Crohn & Colitis Organization, Vienna, Austria. Division of Gastroenterology, AOU Careggi Hospital, Florence, Italy. $7 gn_A_00007132
700    1_
$a Peyrin-Biroulet, L $u Gastroenterology, Inserm U954, University Hospital of Nancy-Brabois, Université Henri Poincaré, Vandoeuvre-lès-Nancy, France.
700    1_
$a Lakatos, P L $u EPICOM, European Crohn & Colitis Organization, Vienna, Austria. 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
773    0_
$w MED00009085 $t Alimentary pharmacology & therapeutics $x 1365-2036 $g Roč. 43, č. 3 (2016), s. 346-55
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26582737 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161018094911 $b ABA008
999    __
$a ok $b bmc $g 1166257 $s 952573
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 43 $c 3 $d 346-55 $e 20151118 $i 1365-2036 $m Alimentary pharmacology & therapeutics $n Aliment Pharmacol Ther $x MED00009085
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...